Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $24,728 | 1,583 | 98.7% |
| Education | $333.11 | 14 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,969 | 236 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,644 | 115 | $0 (2024) |
| Novo Nordisk Inc | $1,739 | 131 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,585 | 106 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,557 | 76 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,432 | 95 | $0 (2024) |
| Lilly USA, LLC | $1,124 | 77 | $0 (2024) |
| Amgen Inc. | $978.90 | 52 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $936.41 | 65 | $0 (2024) |
| PFIZER INC. | $873.86 | 86 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,432 | 140 | ABBVIE INC. ($743.73) |
| 2023 | $3,312 | 200 | ABBVIE INC. ($1,122) |
| 2022 | $3,883 | 232 | ABBVIE INC. ($1,262) |
| 2021 | $3,964 | 263 | AbbVie Inc. ($830.06) |
| 2020 | $3,060 | 226 | AstraZeneca Pharmaceuticals LP ($530.43) |
| 2019 | $3,182 | 205 | Janssen Pharmaceuticals, Inc ($512.15) |
| 2018 | $2,994 | 192 | Boehringer Ingelheim Pharmaceuticals, Inc. ($402.74) |
| 2017 | $2,234 | 139 | AstraZeneca Pharmaceuticals LP ($269.14) |
All Payment Transactions
1,597 individual payment records from CMS Open Payments — Page 1 of 64
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.32 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $24.26 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $8.34 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $20.15 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.04 | General |
| Category: Gastroenterology | ||||||
| 11/23/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $10.33 | General |
| Category: NEUROSCIENCE | ||||||
| 11/20/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 11/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: Diabetes | ||||||
| 11/12/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $11.18 | General |
| Category: RESPIRATORY | ||||||
| 11/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.87 | General |
| Category: NEUROSCIENCE | ||||||
| 11/11/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $11.21 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $34.07 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/01/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.04 | General |
| 10/24/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.50 | General |
| Category: NEUROSCIENCE | ||||||
| 10/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $9.12 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $33.76 | General |
| Category: NEUROSCIENCE | ||||||
| 10/14/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.57 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $24.75 | General |
| Category: PSYCHIATRY | ||||||
| 10/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.54 | General |
| Category: Gastroenterology | ||||||
| 09/30/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $15.97 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 4,372 | 13,146 | $1.1M | $554,334 |
| 2022 | 37 | 5,153 | 13,941 | $1.1M | $573,724 |
| 2021 | 34 | 5,595 | 13,795 | $913,736 | $519,939 |
| 2020 | 47 | 5,720 | 14,205 | $931,163 | $487,881 |
All Medicare Procedures & Services
151 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 414 | 2,081 | $291,340 | $177,119 | 60.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 269 | 2,112 | $211,200 | $93,689 | 44.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 283 | 768 | $69,120 | $48,471 | 70.1% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 85 | 1,343 | $102,068 | $37,740 | 37.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 262 | 262 | $41,920 | $31,574 | 75.3% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 94 | 960 | $91,200 | $30,624 | 33.6% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 93 | 900 | $82,800 | $30,376 | 36.7% |
| 76775 | Limited ultrasound scan behind abdominal cavity | Office | 2023 | 327 | 337 | $53,920 | $13,129 | 24.3% |
| 99484 | Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional | Office | 2023 | 79 | 410 | $22,550 | $12,862 | 57.0% |
| 90756 | Influenza vaccine, quadrivalent derived from cell cultures | Office | 2023 | 233 | 234 | $9,345 | $7,290 | 78.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 234 | 703 | $18,981 | $6,420 | 33.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 226 | 227 | $6,810 | $6,414 | 94.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 36 | 43 | $8,600 | $5,757 | 66.9% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 62 | 163 | $12,225 | $5,658 | 46.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 332 | 332 | $24,900 | $5,423 | 21.8% |
| 90670 | Pneumococcal vaccine, 13-valent | Office | 2023 | 23 | 23 | $6,900 | $5,309 | 76.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 349 | 600 | $9,000 | $5,040 | 56.0% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 32 | 49 | $7,350 | $4,738 | 64.5% |
| 90732 | Pneumococcal vaccine, 23-valent | Office | 2023 | 34 | 34 | $5,950 | $4,316 | 72.5% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 26 | 26 | $5,200 | $4,026 | 77.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 336 | 370 | $24,050 | $3,468 | 14.4% |
| J1040 | Injection, methylprednisolone acetate, 80 mg | Office | 2023 | 223 | 419 | $12,570 | $3,417 | 27.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $2,560 | $1,899 | 74.2% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 12 | 12 | $3,000 | $1,814 | 60.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 22 | 30 | $4,500 | $1,294 | 28.8% |
About Dr. Charles Pewitt, DO
Dr. Charles Pewitt, DO is a Family Medicine healthcare provider based in Jackson, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1740389980.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Pewitt, DO has received a total of $25,061 in payments from pharmaceutical and medical device companies, with $2,432 received in 2024. These payments were reported across 1,597 transactions from 63 companies. The most common payment nature is "Food and Beverage" ($24,728).
As a Medicare-enrolled provider, Pewitt has provided services to 20,840 Medicare beneficiaries, totaling 55,087 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 151 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Jackson, MO
- Active Since 09/22/2006
- Last Updated 07/08/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1740389980
Products in Payments
- UBRELVY (Drug) $2,764
- XARELTO (Drug) $1,157
- FARXIGA (Drug) $1,076
- Ozempic (Drug) $1,019
- VRAYLAR (Drug) $936.44
- TRELEGY ELLIPTA (Drug) $935.77
- ENTRESTO (Drug) $850.46
- BREZTRI (Drug) $809.12
- QULIPTA (Drug) $800.94
- XIFAXAN (Drug) $538.72
- Vascepa (Drug) $519.66
- JARDIANCE (Drug) $488.28
- TRADJENTA (Drug) $471.15
- REXULTI (Drug) $414.17
- Livalo (Drug) $411.03
- SYMBICORT (Drug) $404.14
- Kerendia (Drug) $392.57
- NEXLETOL (Drug) $367.64
- SPIRIVA RESPIMAT (Drug) $356.53
- EMGALITY (Drug) $346.21
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Jackson
Dr. Matt Rosenberg, M.d, M.D
Family Medicine — Payments: $677,942
Dr. Andrea Phillips, M.c, M.C
Family Medicine — Payments: $84,561
Dr. Krishan Gupta, M.d, M.D
Family Medicine — Payments: $26,295
Alexander Osowa, Md, MD
Family Medicine — Payments: $22,911
Dr. Channing Smith, M.d, M.D
Family Medicine — Payments: $22,627
Dr. Stephen Arntz, M.d, M.D
Family Medicine — Payments: $21,354